Why the study?
Does left ventricular chamber size determine the clinical and hemodynamic response to oral hydralazine in patients with severe chronic heart failure?
Does left ventricular chamber size determine the clinical and hemodynamic response to oral hydralazine in patients with severe chronic heart failure?
Left ventricular end-diastolic dimension is a strong predictor of clinical and hemodynamic response to hydralazine in patients with severe chronic heart failure.
No takes yet. Share an insight, caveat, or question.
LVEDD was associated with hydralazine response in severe HF; leaves open whether chamber size should guide vasodilator selection in trials.
Packer et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: